BeiGene Named R&D Achievement of 2015 by BayHelix

BeiGene, a Beijing novel cancer drug developer, received the 2015 R&D Achievement of the Year award from BayHelix. BeiGene won the award for dosing the first China-originated anti-PD-1 mAb in humans, securing US FDA approval of its IND, clearance of its BTK inhibitor (BGB-3111), dosing the first patient in China with its novel RAF dimer inhibitor (BGB-283), and securing over $170 million in financing from China and US institutional investors. BayHelix is an association of global life science leaders of Chinese heritage. More details.... Share this with colleagues: // //